Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 09, 2019 08:01 ET | Source: Innovate Biopharmaceuticals, Inc

Innovate Biopharma Announces Analyst Event on Monday, May 20, 2019, in San Diego

RALEIGH, N.C., May 09, 2019 (GLOBE NEWSWIRE) -- Innovate Biopharmaceuticals, Inc. (“Innovate”) (Nasdaq: INNT), a clinical stage biotechnology company focused on developing novel therapeutics for...
May 01, 2019 16:30 ET | Source: Innovate Biopharmaceuticals, Inc

Innovate Biopharmaceuticals Announces Closing of $8.7 Million Registered Direct Offering

RALEIGH, N.C., May 01, 2019 (GLOBE NEWSWIRE) -- Innovate Biopharmaceuticals, Inc. (NASDAQ: INNT) today announced the closing of its previously announced registered direct offering of 4,318,272...
April 29, 2019 13:19 ET | Source: Innovate Biopharmaceuticals, Inc

Innovate Biopharmaceuticals Announces $8.7 Million Registered Direct Offering Priced At-the-Market

RALEIGH, N.C., April 29, 2019 (GLOBE NEWSWIRE) -- Innovate Biopharmaceuticals, Inc. (NASDAQ: INNT) today announced that it has entered into securities purchase agreements with certain institutional...
April 29, 2019 07:35 ET | Source: Innovate Biopharmaceuticals, Inc

Innovate Biopharmaceuticals Shows Larazotide is the First Drug, with its Novel Mechanism of Action of Re-normalizing the Intestinal Barrier, to Demonstrate Improvements in validated NASH Biomarkers and Endpoints in synergy with obeticholic acid, an FXR agonist, and Reports key first quarter 2019 financial results and operational highlights

Continued execution toward start of the first phase 3 celiac disease clinical trial in the current quarter with key sites for trial launch selected and active recruitment efforts underway NASH Data...
April 26, 2019 12:59 ET | Source: Innovate Biopharmaceuticals, Inc

Innovate Biopharmaceuticals First Quarter 2019 Financial Results and Operational Progress Updates - Webcast Details

RALEIGH, N.C., April 26, 2019 (GLOBE NEWSWIRE) -- Innovate Biopharmaceuticals, Inc. (“Innovate”) (Nasdaq: INNT), a clinical stage biotechnology company focused on developing novel autoimmune and...
April 11, 2019 09:45 ET | Source: Innovate Biopharmaceuticals, Inc

Innovate Biopharmaceuticals Presents Oral Poster at European Association for the Study of the Liver (EASL) Demonstrating Positive Effect of Larazotide on Reduced Intestinal Permeability in a NASH Preclinical Study

Selected for oral poster tour by the scientific committee in the gut microbiota section at the International Liver CongressTM 2019 of EASL Data presented as a poster showing significant effect on gut...
April 02, 2019 11:34 ET | Source: Beyond Celiac

Five Reasons to Pay Attention to the 2019 Beyond Celiac Research Symposium

Philadelphia, PA, April 02, 2019 (GLOBE NEWSWIRE) -- When Beyond Celiac hosts its third annual Research Symposium on May 30, 2019, in Philadelphia, three leading experts led by Beyond Celiac CSO and...
April 02, 2019 07:00 ET | Source: Innovate Biopharmaceuticals, Inc

Innovate Biopharmaceuticals to Announce First Quarter 2019 Financial Results and to Provide Operational Progress Updates on April 29, 2019

Innovate plans to provide an operational progress update, including regarding its first phase 3 celiac disease clinical trial Topline NASH preclinical data expected to be released at the Digestive...
March 26, 2019 09:32 ET | Source: Innovate Biopharmaceuticals, Inc

Innovate Biopharmaceuticals Announces Collaboration with Institut Gustave Roussy to Study Regulation of Intestinal Permeability and the Gut Microbiota using Larazotide in Immuno-oncology Checkpoint Inhibitor Failure Pre-Clinical Models

RALEIGH, N.C., March 26, 2019 (GLOBE NEWSWIRE) -- Innovate Biopharmaceuticals Inc. (Nasdaq: INNT), a clinical stage biotechnology company focused on developing novel therapeutics for autoimmune and...
March 19, 2019 07:45 ET | Source: Innovate Biopharmaceuticals, Inc

Innovate Biopharmaceuticals Reports Financing to Initiate the First Phase 3 Clinical Trial in Celiac Disease, Fiscal Year 2018 Earnings and Key Corporate Highlights

Innovate closes an equity financing with gross proceeds of $9.7 million Continued launch activities for start of the first Phase 3 celiac disease trial, expected to start Q2 2019 Continued research...